Advertisements

Omeclamox-Pak

Quick links to important sections

Omeclamox-Pak

Selected form

Advertisements
Advertisements

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Omeclamox-Pak

Quick Facts

Property Description
Active Ingredients Amoxicillin, Clarithromycin, Omeprazole
Form Copackaged Kit (Delayed-Release Capsules and Tablets)
Pharmacological Class H. pylori Eradication Agents / Triple Therapy
Common Use Targeting the H. pylori bacteria associated with ulcers
Distinctive Feature Unit-of-use packaging for sequential dosing

What is Omeclamox-Pak and What Type of Therapy Is It?

Omeclamox-Pak is a prescription-only copackaged combination product indicated for specific gastrointestinal therapy, manufactured by Cumberland Pharmaceuticals Inc. It is definitively classified as an H. pylori Eradication Agent because its primary therapeutic focus is the elimination of the Helicobacter pylori pathogen, a bacteria strongly associated with peptic ulcer disease.

This formulation is structurally defined as a complete triple therapy regimen, where three distinct medications are supplied together in a unit-of-use kit, enabling synchronized oral route administration. This unique co-packaging feature is intended to support patient compliance with the intensive treatment protocol required for successfully eradicating the resilient pathogen. The regimen is a standard option when local resistance to its key antibiotic components is low.

Active Ingredients, Forms, and Origin of Omeclamox-Pak

The composition of Omeclamox-Pak contains three essential active ingredients: Amoxicillin, Clarithromycin, and Omeprazole. These compounds are all synthetic in origin and represent three different pharmacological classes: Amoxicillin is a Penicillin Antibiotic, Clarithromycin is a Macrolide Antibiotic, and Omeprazole is a Proton Pump Inhibitor (PPI).

The ingredients are provided as separate dosage forms within the kit: Amoxicillin typically as a capsule, Clarithromycin as a tablet, and Omeprazole as a specialized Delayed-Release Capsule. This combination of classes is widely supported by treatment guidelines as an effective first-line approach for H. pylori infections.

What is the General Purpose of This Combination?

The general purpose of this combination is to achieve bacterial eradication while concurrently promoting the healing of the gastrointestinal lining. The combined antibiotics collaborate to eliminate the H. pylori pathogen from the digestive system. Simultaneously, the inclusion of the acid-suppressing agent, Omeprazole, provides sustained acid suppression, which is vital for enhancing the activity of the antibiotics and reducing the acidic stress on the stomach and intestinal lining, allowing the tissue to undergo necessary repair.

Regulatory References

  1. NIH DailyMed Label for OMECLAMOX-PAK
  2. Maastricht VI/Florence Consensus Report on H. pylori (European Guidelines)
Advertisements

What side effects are possible with Omeclamox-Pak?

Possible Side Effects and Safety Information

Official regulatory documentation structures the safety profile of Omeclamox-Pak around the combined adverse reactions of its three components (Amoxicillin, Clarithromycin, and Omeprazole). Adverse reactions are formally classified by frequency and grouped into System-Organ-Classes, consistent with regulatory standards.

Commonly Documented Adverse Reactions

Adverse reactions classified as common in official labeling include effects on the Gastrointestinal System, such as Diarrhea, Nausea, Vomiting, and Abdominal Pain. Dysgeusia (taste perversion) and Headache are also frequently reported events.


Serious Adverse Reactions and Constraints

The regulatory profile explicitly documents rare but serious adverse reactions. These include severe Hypersensitivity Reactions such as Anaphylaxis, and serious skin conditions like Stevens-Johnson Syndrome (SJS). The risks of Clostridioides difficile-associated diarrhea (CDAD) and Hepatotoxicity (severe liver injury) are also noted in regulatory information. Due to the Amoxicillin component, the product is strictly contraindicated in individuals with a history of penicillin allergy.

Population and Duration-Related Safety Patterns

Specific safety considerations are defined for certain populations. The product is advised to be avoided in patients with pre-existing hepatic impairment. Older adults may be at increased risk for certain serious effects, warranting caution. Furthermore, risks associated with the duration of exposure are documented; prolonged use of the Omeprazole component is associated with an increased risk for bone fractures and hypomagnesemia (low magnesium levels), which are safety concerns tied to extended duration of use.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

This section describes the documented clinical manifestations and regulator-mandated emergency actions for overdose with Omeclamox-Pak, based strictly on official prescribing information.

Documented Overdose Manifestations

Official regulatory summaries document that an overdose may present with specific symptoms affecting multiple body systems:

  • Gastrointestinal: Nausea, vomiting, diarrhea, and stomach pain or cramps.
  • Central Nervous System (CNS): Confusion, drowsiness, headache, and blurred vision.
  • Cardiovascular: Fast or pounding heartbeat (tachycardia) and flushing.
  • Other Systemic: Sweating, dry mouth, and decreased urination.

Emergency Actions and Required Medical Attention

Regulatory authorities provide explicit guidance on when urgent medical assistance must be sought:

  • Immediate Emergency Services: Contact emergency services (911) immediately if the affected individual experiences life-threatening symptoms such as collapse, a seizure, trouble breathing, or inability to be awakened.
  • Poison Control: Seek immediate medical attention or call the Poison Help line for current information on the treatment of drug overdose.

There is no specific pharmacological antidote documented in the official prescribing information. Overdose management is based on the protocol of instituting symptomatic and supportive treatment.

Advertisements

Therapeutic Uses of Omeclamox-Pak

What Omeclamox-Pak Treats: Main Uses and Benefits

Omeclamox-Pak is used in situations involving certain distressing symptoms associated with upper gastrointestinal disease. The treatment is commonly used when short-term symptomatic assistance is needed. This combination therapy is applied across domains where the goal is the eradication of H. pylori in contexts involving conditions marked by fluctuating symptoms.


Eradicating and Supporting Stability

The core therapeutic benefit is relevant for conditions characterized by episodic or fluctuating manifestations. This action is relevant in clinical settings marked by increased discomfort or tension, and may assist in reducing the risk of recurrent ulcer episodes. The regimen is also commonly used across conditions presenting with acute episodes where functional stability becomes affected. This assists with maintaining comfort during symptomatic phases.

Relieving Associated Symptom Clusters

This medicine helps address symptom clusters that create noticeable physiological strain, such as symptoms related to physical discomfort and symptoms related to inflammatory or irritative states. This provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load.


Quick Fact: Supports the easing of symptoms related to systemic imbalance

Regulatory References

  1. NIH DailyMed overview
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Omeclamox-Pak?

Eligibility for Omeclamox-Pak is strictly defined by regulatory guidelines for the adult population (age 18 years and older) for H. pylori eradication in the context of duodenal ulcer disease. Safety and efficacy have not been established in the pediatric population (under 18 years of age).

Absolute Prohibitions (Contraindications)

The medicine must not be used by patients who have a history of hypersensitivity to any of its components: omeprazole, any macrolide antibiotic (such as clarithromycin), or any penicillin antibiotic (such as amoxicillin). Use is also formally contraindicated if the patient is coadministering certain drugs, including Pimozide, Ergotamine, or Dihydroergotamine.

Restricted and Conditional Use

The official label advises to avoid use in patients with documented Hepatic Impairment. Use is highly restricted during pregnancy, where it should be used only if no appropriate alternative therapy exists. Nursing mothers are directed to discontinue or discard milk during treatment. Additionally, conditions such as Myasthenia Gravis require monitoring, and Gastric Malignancy must be ruled out before starting therapy.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Omeclamox-Pak is structured around constraints identified in regulatory documentation for its three active components.

Formal Contraindications

Coadministration of Omeclamox-Pak is formally contraindicated with certain drugs due to the risk of serious adverse reactions, specifically:

  • Pimozide
  • Ergotamine and Dihydroergotamine

Exposure-Altering Interactions

Interactions are defined by official documentation as resulting in either increased or decreased drug exposure:

Mechanism / Constraint Interacting Medicines (Examples)
CYP3A4 Inhibition (Clarithromycin) Increases systemic exposure of Sildenafil, Carbamazepine, Theophylline, and certain Statins.
Reduced Gastric pH (Omeprazole) Reduces plasma concentrations of Atazanavir and Nelfinavir (co-use not recommended); also affects Iron salts and Ketoconazole.
CYP450 System Effect (Omeprazole) Prolongs the elimination of drugs like Diazepam, Phenytoin, and Warfarin.
Other Pharmacokinetic Effect Probenecid may increase Amoxicillin blood concentrations.

Pharmacodynamic Risk and Monitoring

Official labeling identifies specific additive risks and monitoring constraints. Concurrent use with Colchicine has resulted in reports of fatal toxicity, specifically noted in the elderly with renal insufficiency. Co-use with antiarrhythmics like Quinidine or Disopyramide requires ECG monitoring due to the risk of arrhythmias. Additionally, the use of Omeclamox-Pak should be avoided in individuals with hepatic impairment.

Advertisements

Mechanism of Action

How Omeclamox-Pak Works: Mechanism of Action

This medication functions through the synergistic interaction of three distinct mechanisms. Omeprazole acts as an acid-activated prodrug, leading to the irreversible inhibition of the gastric parietal cell H^+, K^+- ATPase (the proton pump). This blockade of the final step in acid secretion results in a sustained reduction in gastric acidity (hypochlorhydria).

This alteration in pH supports the chemical stability and activity of the two antibiotic components against the target organism. Amoxicillin interferes with bacterial cell wall synthesis by inhibiting transpeptidases, causing structural failure and cell death. Concurrently, Clarithromycin disrupts bacterial metabolism by binding to the 50S ribosomal subunit, which halts essential protein synthesis. This combined activity leads to widespread cell death and reduction of the target microbial population, resulting in changes to the gastric environment's chemical and biological state.

Advertisements

Dosage and Administration Information

How to Use Omeclamox-Pak: Official Administration Guidelines

Omeclamox-Pak is a unit-of-use copackaged kit providing a triple therapy regimen for oral administration, structured around specific timing and dosage rules. The primary course involves the synchronous use of all three components—Omeprazole (a proton pump inhibitor), Clarithromycin (a macrolide antibiotic), and Amoxicillin (a penicillin-class antibiotic)—administered twice daily for a fixed duration.


Standard Dosing Regimen

Component Strength Per Dose Frequency Timing
Omeprazole (Delayed-Release) 20 mg (1 capsule) Twice Daily (BID) Before a meal
Clarithromycin 500 mg (1 tablet) Twice Daily (BID) Before a meal
Amoxicillin 1000 mg (2 capsules) Twice Daily (BID) Before a meal

The complete dose—one Omeprazole capsule, one Clarithromycin tablet, and two Amoxicillin capsules—must be taken together every morning and evening. This administration must occur before eating a meal (on an empty stomach).


Procedural Constraints and Duration

The standard duration for this combined therapy is 10 days. The dosage forms must be swallowed whole; they should not be crushed, chewed, or opened, as this compromises the specialized delayed-release formulation of the Omeprazole component.

For patients who have an active duodenal ulcer at the start of treatment, the 10-day triple therapy is followed by a course of Omeprazole 20 mg once daily for an additional 18 days. Safety and efficacy for use in the pediatric population have not been established, and use is generally avoided in patients with known severe hepatic impairment. If a dose is missed, it should not be doubled, and the patient should resume the prescribed schedule at the next regularly scheduled time.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Primary Indication

Research has explored the agent within the research setting for the primary condition. Investigators examined the potential impact on quality of life in patients involved in the studies.

The combination therapy was evaluated in research involving patients who met specific criteria. Researchers assessed whether the combination was linked to changes in bone density and fracture risk.

Agent Characteristics and Study Observations

Clinical trials investigated the characteristics of the agent.

Studies assessed the changes in symptoms and the time frame of these changes in participants. Findings from some studies suggest a potential difference in observations between various dosing regimens explored, though the results were mixed. Studies examined whether the agent was associated with changes in joint inflammation markers.

Safety and Tolerability Profiles

Long-term safety profiles in adults have been evaluated in research. The doses studied in the research were often between 10 mg and 20 mg daily. The frequency and severity of reported side effects were documented in the studies.

Observation Category Description
Commonly Documented Events Reported side effects included headache and fatigue in a minority of participants.
Serious Events A small number of serious events were documented across various trials. Research has explored potential risk factors, including a history of heart issues.

Studies explored the agent's absorption profile when administered with food. It is not yet clear whether this impacts clinical observations.

Key Studies & References

  1. Newly Published Data Demonstrates 85% Eradication of Ulcer Causing Bacteria: Study supports use of Omeclamox®-Pak as first-line treatment for H. pylori
  2. The combination of omeprazole, amoxycillin, and clarithromycin eradicates Helicobacter pylori in 95% of patients—7 days of therapy is as good as 10 days
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Omeclamox-Pak (FAQ)


Q: Is Omeclamox-Pak the same as taking separate omeprazole, amoxicillin, and clarithromycin pills?

Omeclamox-Pak is officially classified as a copackaged unit-of-use kit that provides the three separate medications needed for the treatment. This specific packaging is designed to help support patient adherence to the precise, synchronized dosing schedule required for the full triple therapy regimen, which is important for successful bacterial eradication.


Q: How quickly does Omeclamox-Pak start working on the issue it treats?

The Omeprazole component, which is an acid-suppressing agent, typically begins its action within an hour of administration. While acid suppression starts quickly, the overall goal of H. pylori eradication relies on the continuous, combined action of all three drugs over the entire fixed duration of the treatment course.


Q: Do I need to take Omeclamox-Pak with food?

Official administration instructions specify that the medicine should be taken before a meal (on an empty stomach) twice daily. Taking the medication at the time directed is necessary to ensure the proper absorption and activity of the drug components.


Q: Is a metallic taste common when using Omeclamox-Pak?

Yes, official adverse event reporting lists taste perversion (dysgeusia) as a common reaction in clinical trials. This effect is often described by patients as a temporary metallic or unusual taste in the mouth.


Q: Can Omeclamox-Pak be taken with common pain relievers like ibuprofen?

Official drug labeling indicates that the Omeprazole component can affect the metabolism of other drugs in the liver, which may include certain pain relievers. While specific non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are not formal contraindications, official information emphasizes the importance of reviewing all potential drug-drug interactions with a healthcare provider.


Q: Are there food restrictions when taking Omeclamox-Pak?

While the drug is required to be taken before a meal, official labeling notes that grapefruit juice may affect the metabolism of the Clarithromycin component. Beyond the requirement for fasting before the dose, no other specific food restrictions are typically listed in the core regulatory documents.


Q: Is Omeclamox-Pak safe for use during pregnancy?

According to official regulatory documents, Omeclamox-Pak is not generally recommended for use in pregnant women unless an appropriate alternative therapy does not exist. Based on animal studies for the components, the medicine may carry a potential risk of harm to the developing fetus, and regulatory information states that patients should be aware of the potential risk to the fetus.


Q: Why is it called a 'Pak' or a 'Convenience Pack'?

It is referred to as a 'Pak' or 'Unit-of-Use' kit because it is a copackaged combination product designed to simplify the complex, multi-drug dosing schedule. This feature is intended to help support patient adherence to the full 10-day treatment regimen needed for successful H. pylori eradication.


Q: Can Omeclamox-Pak cause yeast infections?

Official warnings note that the use of antibiotics, which are part of this treatment, carries a risk of superinfection. This risk is due to the potential for the antibiotic to cause the overgrowth of non-susceptible organisms, including fungi, which can result in infections like candidiasis (a yeast infection).


Q: Can Omeclamox-Pak affect the birth control pill?

Official labeling for the Amoxicillin component notes that penicillins may potentially reduce the effectiveness of oral contraceptives. The mechanism is theorized to involve the antibiotic affecting the normal gut bacteria that plays a role in the body's reabsorption of estrogen.


Q: What happens if I stop taking Omeclamox-Pak early?

Official warnings strongly discourage stopping the treatment early. Failure to complete the entire fixed course may prevent the full elimination of the target bacteria, leading to the recurrence of the infection. In addition, incomplete treatment increases the risk of developing drug-resistant bacteria that are difficult to treat.


Q: Why is it important to complete the full course of Omeclamox-Pak?

Completing the full course is considered essential to successfully achieve the treatment’s primary goal, which is the eradication of H. pylori. The entire regimen is necessary to minimize the risk of treatment failure and the development of drug-resistant bacteria.


Q: Can Omeclamox-Pak affect sleep or cause dizziness?

Adverse event reporting for the drug components lists effects on the central nervous system. Documented events include insomnia (difficulty sleeping) and post-marketing reports have noted occurrences of dizziness and confusion among patients using the combination's ingredients.


Q: Are there any common herbal supplements or vitamins that interact with Omeclamox-Pak?

The official Omeprazole labeling explicitly mentions that co-use with the herbal product St. John's Wort may reduce the concentration of Omeprazole in the body. General interactions with common vitamins are typically not listed in the core regulatory documents.


Q: Is it okay to drink alcohol while using Omeclamox-Pak?

Official labeling does not list a specific formal contraindication against consuming alcohol. However, general healthcare guidelines often advise against using alcohol during antibiotic treatment due to the potential for increased common side effects such as nausea, dizziness, or stomach irritation.


Q: Can Omeclamox-Pak affect the results of other medical tests?

The Amoxicillin component can cause false-positive reactions when certain copper-reduction tests are used to check for glucose in the urine. Regulatory documentation indicates that tests based on the enzymatic glucose oxidase reaction should be used instead to prevent inaccurate results.


Q: Can Omeclamox-Pak cause dark urine or light-colored stools?

Official warnings describe the potential for rare but serious liver problems (Hepatotoxicity). Signs of serious liver issues noted in post-marketing reports include the occurrence of dark urine, light-colored stools, or jaundice (yellowing of the skin or eyes).


Q: Does Omeclamox-Pak contain sulfa?

The active ingredients are Amoxicillin, Clarithromycin, and Omeprazole. Official composition data confirms that none of these three active ingredients are chemically classified as sulfa-containing (sulfonamide) drugs.


Q: What happens to the remaining tablets if the course is not finished?

Official disposal guidance for unused or outdated medication recommends consulting a healthcare professional for the proper method. Patients are advised to utilize drug take-back programs when available, as the medication should not be kept after the course is complete.


Q: Is Omeclamox-Pak used to treat regular stomach acid issues?

Omeclamox-Pak is only indicated and approved for the treatment of H. pylori infection to reduce the risk of duodenal ulcer recurrence. It is not indicated or approved for treating general or non-H. pylori-related stomach acid issues.


Q: Can I take Omeclamox-Pak if I have a history of heart rhythm issues?

Official warnings note that the Clarithromycin component has the potential to cause a serious heart problem and that a higher risk may exist for patients with pre-existing heart rhythm problems (QT prolongation). Co-use with antiarrhythmic medicines requires careful monitoring.


Q: Are there official registry studies about Omeclamox-Pak?

Official labeling references the clinical trials that established the efficacy of the combination therapy. While specific registry studies may not be named in the core document, the drug’s safety information is continuously collected and updated based on ongoing post-marketing surveillance reports.

Advertisements

How should Omeclamox-Pak be stored and disposed of?

Omeclamox-Pak requires storage within a strictly defined environmental profile to preserve the stability of its three components. The medication must be stored at controlled room temperature between 20 C and 25 C (68 F and 77 F). The official label permits temperature excursions up to 30 C (86 F).

Protection and Container Rules

Storage mandates protection from moisture and light and explicitly requires the product be kept from freezing and away from excess heat. The kit must remain in its original, tightly closed container, and patients should not use the medication if the blister packaging is torn or broken. As with all medications, Omeclamox-Pak must be stored out of the reach of children.

Disposal Requirements

Official disposal guidance recommends that unused or outdated medication be discarded after consulting a healthcare professional for the proper method. The FDA generally advises utilizing drug take-back programs when available or disposing of the medicine in household trash after mixing it with an unpalatable substance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omeclamox-Pak found in:

A-Z Index: